- Home
- / Ultragenyx
Ultragenyx
Stock Price
$53.1
2024-10-28
Market Capitalization
$4.9 B
2024-10-28
Revenue
$560.2 M
FY, 2024
Ultragenyx Summary
Company Summary
- Overview
- Ultragenyx Pharmaceutical is a company that develops therapies for rare genetic diseases. It offers DOJOLVI, a treatment for children and adults with long-chain fatty acid oxidation disorders (LC-FAOD), and MEPSEVII, an enzyme replacement therapy (ERT) for mucopolysaccharidosis (MPS) VII.
- Type
- Public
- Status
- Active
- Founded
- 2010
- HQ
- Novato, CA, US | view all locations
- Website
- https://www.ultragenyx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Howard Horn, Chief Financial Officer and Executive Vice President, Corporate Strategy
Dennis Huang, Chief Technical Operations Officer and Executive Vice President, Gene Therapy Research and Development
Eric Crombez, Chief Medical Officer and Executive Vice President
Operating MetricsView all
Facilities Owned
1
FY, 2022
Facilities Leased
7
FY, 2022
Trials Products Approved
4
FY, 2022
LocationsView all
15 locations detected
Novato, CA HQ
United States
60 Leveroni Ct
Bedford, MA
United States
170 Middlesex Turnpike
Brisbane, CA
United States
5000 Marina Blvd
Miami, FL
United States
703 Waterford Way, suite 890
Somerville, MA
United States
100 Chestnut St
Woburn, MA
United States
19 Presidential Way 150 Presidential Way
Ultragenyx Financials
Summary Financials
- Revenue (Q1, 2025)
- $139.3M
- Net income (Q1, 2025)
- ($151.1M)
- Cash (Q1, 2025)
- $127.1M
- EBIT (Q1, 2025)
- ($142.9M)
- Enterprise value
- $4.8B